



New 1,3,4-Oxadiazolyl-pyrazolyl-Pyridine Tricyclic Scaffold Derivatives: Synthesis and Structure Assignment by NMR and DFT Calculations

Gisele R. Paim (PQ)^{*1}, Susiane C. Meira (PG)², Everton P. Pittaluga (PG)², Liliane M. F. Porte (PQ)², Alexandre R. Meyer (PG)², Jussara Navarini (PQ)³, Helio G. Bonacorso (PQ)².

¹ Instituto Federal Farroupilha – Campus Júlio de Castilhos 98130-000, Júlio de Castilhos, RS.

² Núcleo de Química de Heterociclos (NUQUIMHE), Departamento de Química, Universidade Federal de Santa Maria 97015-900, Santa Maria, RS.

³ Instituto Federal Farroupilha – Campus Alegrete 97555-000, Alegrete, RS.

*gi_quimica@jc.iffarroupilha.edu.br.

Keywords: 1,3,4-oxadiazoles, pyridine, DFT calculations

INTRODUCTION

Among five-membered aromatic heterocycles, 1,3,4-oxadiazoles are important class of aromatic heterocycles displaying a broad spectrum of biological activities, such as antimicrobial, anti-inflammatory, analgesic, anticonvulsant, anti-hypoglycemic.¹ Compounds containing oxadiazole moieties have been described as possessing anticancer or muscle relaxant activity and have been used as fluorescent whiteners.² Usually, the synthesis of non-symmetrical 2,5-disubstituted 1,3,4-oxadiazoles has mainly been done by dehydration of diacylhydrazines or oxidative cyclization of aldehyde *N*-acylhydrazones, but many other reagents and reaction conditions have been reported to achieve their obtainment.³

RESULTS AND DISCUSSION

Following our previous work⁴ and in attempting to introduce another class of nitrogenated azoles into the pyrazolyl-pyridine system, compounds methyl 6-[alkyl/aryl-5-trifluoro-methyl-1*H*-pyrazol-1-yl]nicotinate hydrochloride **1a-b** were reacted firstly with hydrazine hydrate under reflux of ethanol to give the hydrazides of **2a-b**. These hydrazides were submitted to a cyclocondensation reaction with R¹C(OEt)₃ (**3**), where R¹ = methyl (**3a**) and phenyl (**3b**), leading to the obtention of four examples of oxadiazolyl-pyrazolyl-pyridines (**4aa-bb**), at moderate yields (Scheme 1). As the reaction property, the orthoesters were used simultaneously as solvent

and reagent and compounds of **4aa-bb** precipitated steadily during the reaction time at 110 °C. Compounds **4aa-bb** were characterized by ¹H and ¹³C NMR spectroscopy and thus, in order to assign the conformation of the oxadiazolyl-pyrazolyl-pyridines (**4**) we employed theoretical calculations using the Density Functional Theory (DFT) method.⁵

CONCLUSION


To demonstrate the applicability of the esters **1**, new hydrazides **2** and their oxadiazolyl-pyrazolyl-pyridines **4** were able to be produced as a new triheterocyclic scaffold at moderate yields.

ACKNOWLEDGEMENTS

Instituto Federal Farroupilha- Campus Júlio de Castilhos, UFSM, CAPES, CNPq

REFERENCES

- (a) Gaonkar, S. L.; Rai, K. M. L.; Prabhuswamy, B. *Eur J Med Chem* **2006**, *41*, 841. (b) Macaev, F.; Rusu, G.; Pogrebnoi, S.; Gudima, A.; Stingaci, E.; Vlad, L.; Shvets, N.; Kandemirli, F.; Dimoglo, A.; Reynolds, R. *Bioorg Med Chem* **2005**, *13*, 4842. (c) Zheng, X.; Li, Z.; Wang, Y.; Chen, W.; Huang, O.; Liu, C.; Song, C. *J Fluorine Chem* **2003**, *123*, 163.
- Bhatt, J. J.; Shah, B. R.; Shah, H. P.; Trivedi, P. B.; Undavia, N. K.; Desai, N. C. *J Indian Chem* **1994**, *33B*, 189.
- (a) Weaver, G. W. In *Science of Synthesis*; Storr, R. C.; Gilchrist, T. L., Eds.; Thieme: Stuttgart, **2004**; *13*, 219; (b) Hill, J. In *Comprehensive Heterocyclic Chemistry II*; Storr, R. C., Ed. Pergamon, Oxford, **1996**; *4*, 267 and 905 (c) Dobrotă, C.; Paraschivescu, C. C.; Dumitru, I.; Matache, M.; Baci, I.; Rută, L. L. *Tetrahedron Lett* **2009**, *50*, 1886 and references therein.
- Bonacorso, H. G.; Paim, G. R.; Porte, L. M. F.; Pittaluga, E. P.; Martins, M. A. P.; Zanatta, N. *ARKIVOC* **2012**, *viii*, 214.
- Gaussian 09, Revision A.1, Frisch, M. J. *et al* Gaussian, Inc., Wallingford CT, 2009.



Scheme 1. Reagents and conditions: (i) NH₂NH₂·H₂O, EtOH, reflux, 20 h; (ii) (**3**) R¹C(OEt)₃, 110 °C, 16 h. R = Me, Ph; R¹ = Me, Ph.